Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen's Murdo Gordon On Generating Sales Growth In A Challenging Commercial Year

Jul 26 2019

• By Mandy Jackson

Amgen Commercial Chief Murdo Gordon

Related Content

Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha

Dec 02 2017

Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price

May 18 2018

‘Disappointed’ UCB And Amgen Will Appeal CHMP’s Negative Evenity Decision

Jun 28 2019

Q&A: SVP Elliott Levy On Amgen R&D's 'Singular Focus On Innovation'

Jun 18 2019

Amgen Explains How Big A Hit It May Take From Biosimilars, Pricing Pressures

Jan 30 2019

US Market For Therapeutic Cancer Biosimilars Will Be Tested By Mvasi, Kanjinti Launches

Jul 19 2019

In A Win For Amgen, Court Blocks Sanofi/Regeneron's Praluent Sales In Germany

Jul 12 2019

Amgen Launches Evenity For High-Risk Osteoporosis At $21,900 List Price

Apr 16 2019

Lower-Cost Competitors Hit Amgen's Blockbusters

May 01 2019

Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use

Oct 25 2018

Related Companies

Amgen, Inc.

Allergan plc

Roche Holding AG

Sanofi

Regeneron Pharmaceuticals, Inc.

UCB S.A.

Novartis AG

Eli Lilly and Company

Teva Pharmaceutical Industries Ltd.

Additional Topics

Sales & Earnings Commercial Business Strategies Biosimilars BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window